Antiandrogen Therapy, Abiraterone Acetate, and Prednisone in Treating Participants with Stage IV Castration Resistant Prostate Cancer
This early phase I trial studies how antiandrogen therapy, abiraterone acetate, and prednisone work in treating participants with stage IV castration resistant prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as antiandrogen therapy, abiraterone acetate, and prednisone may lessen the amount of androgen made by the body.
- Histologically or cytologically confirmed adenocarcinoma of the prostate
- High risk mCSPC as defined by the Latitude study (>= 2 of 3 risk factors: Gleason >= 8, >= 3 bone lesions, or measurable visceral metastases)
- > 75% PSA decline after 12 weeks of run in period with ADT, abiraterone plus prednisone
- Performance status Eastern Cooperative Oncology Group (ECOG) 0-1
- Serum alanine aminotransferase (ALT) or aspirate aminotransferase (AST) must be < 2.5 x upper limit of normal (ULN)
- Total bilirubin < 1.5 X ULN
- Estimated creatinine clearance must be > 40 mL/min
- Absolute neutrophil count (ANC) > 1500/l
- Hemoglobin above 9 g/dl
- Platelet count > 100,000/l
- Stable medical condition, including the absence of acute exacerbations of chronic illnesses, serious infections or major surgery within 28 days prior to study enrollment
- Ability to give written informed consent
- Prior ADT with GnRH analogue for non-metastatic prostate cancer within 2 years prior to study enrollment; or > 3 months of GnRH analog in the metastatic setting
- Prior treatments with TAK-700/Orteronel, abiraterone, ketoconazole, apalutamide, or enzalutamide
- Documented central nervous system metastases or liver metastasis
- Requiring opioids for cancer related pain
- Prior surgical castration
- Treatment with any investigational compound within 30 days prior to the first dose of study drugs
- Diagnosis or treatment for another systemic malignancy within 2 years before the first dose of study drugs, or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
- Uncontrolled hypertension despite appropriate medical therapy (blood pressure of greater than 160 mmHg systolic and 90 mmHg diastolic at 2 separate measurements no more than 60 minutes apart during the screening period). Note: Patients may be rescreened after adjustments of antihypertensive medications
- Unstable symptomatic ischemic heart disease, ongoing arrhythmias of grade > 2 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], version 5.0), New York Association class III or IV heart failure
- Known human immunodeficiency virus (HIV) infection, active chronic hepatitis B or C not contained with anti-viral therapy, life threatening illness unrelated to cancer, or any serious medical or psychiatric illness that could, in investigator’s opinion, potentially interfere with participation in this study
- Known gastrointestinal (GI) disease or GI procedure that could interfere with the GI absorption or tolerance of study drugs, including difficulty swallowing tables
- Subjects with delayed healing of wounds, ulcers, and/or bone fractures
- Inability to comply with protocol requirements
Locations & Contacts
Contact: Jingsong Zhang
Trial Objectives and Outline
I. Test the feasibility of adaptive antiandrogen therapy (androgen deprivation therapy [ADT]) in patients with high risk metastatic castration sensitive prostate cancer (mCSPC).
I. Assess the clinical benefits of adaptive ADT by comparing to historical controls.
EXPLORATORY/CORRELATIVE STUDIES OBJECTIVES:
I. Detect the intra-tumor heterogeneity of androgen receptor (AR) and Cyp17 IHC stains on formalin-fixed paraffin-embedded (FFPE) blocks of prostate tumors and or metastatic lesions.
II. Refine the mathematical model for adaptive ADT.
III. To develop imaging habitat biomarkers to track diseases progression using the patients’ computed tomography (CT) and bone scans and compare with conventional progression variables (like prostate specific antigen [PSA]).
IV. Compare the AR, Cyp17 immunohistochemistry (IHC) stains as well as imaging biomarkers with a retrospective cohort of mCSPC patients who underwent continuous ADT as standard of care.
Participants receive standard of care ADT via injections and gonadotrophin releasing hormone (GnRH) such as leuprolide acetate, goserelin acetate, or triptorelin for 4 weeks in the absence of disease progression or unacceptable toxicity. Participants then receive ADT, abiraterone acetate orally (PO), and prednisone PO once daily (QD) for 8 weeks in the absence of disease progression of unacceptable toxicity. Participants who PSA reaches 2 folds or higher of baseline PSA, may restart treatment.
Trial Phase & Type
No phase specified
Moffitt Cancer Center
Secondary IDs NCI-2018-01095
Clinicaltrials.gov ID NCT03511196